The utility of [ 18 F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate Resistant Prostate Cancer Patients (nmCRPCp): Diagnostic performance and Impact on Management.
Moataz A S SolimanKareem ElfatairyReham Mohammed Ibrahim EllessyYury S VelichkoRyan AveryLinda C KelahanAshley E RossHatice SavasPublished in: The British journal of radiology (2023)
F]Fluciclovine PET/CT guiding management change for nonmetastatic castrate-resistant prostate cancer patients, particularly those with oligometastatic disease.